Caszyme, nSAGE, and Vilnius University Consortium Aims to UNCOVER New Insights With Diagnostics Platform Co-Development

Original from: Caszyme

nSAGE, Caszyme, and Vilnius University have joined forces to form a consortium which will develop a new, advanced diagnostics solution. The UNCOVER project will develop a universal, CRISPR-based diagnostics platform for accurate and rapid detection of infectious diseases. This platform will be versatile, user-friendly, applicable to both human and animal health, and will be easily programable to address a wide range of pathogens and disease biomarkers.

UNCOVER will utilize advanced bioinformatics and protein engineering technologies, with the consortium planning to discover novel and optimise existing Cas proteins to improve their sensitivities and specificities.

The platform will undergo validation with patient samples and will address a critical gap in Point-of-Care diagnostics thus advancing local and global disease detection capabilities.

“By utilizing the intrinsic signal amplification of the Type III CRISPR system, we aim to develop a next-generation detection platform with broad applications in healthcare and molecular diagnostics,” says Dr. Gintautas Tamulaitis, Research Professor at Vilnius University.

“Partnerships are the essential link connecting unique expertise to innovative solutions. Through our collaborative efforts with nSAGE and Vilnius University, we are harnessing the full potential of CRISPR’s versatility, aiming to translate it into tangible tools for diagnostics. The UNCOVER project aligns with Caszyme’s commitment to developing high-quality CRISPR-based solutions,” says Dr. Monika Paule, CEO and Co-Founder of Caszyme.

“To achieve improved sensitivity and specificity of the detection platform, we are going to leverage our deep knowledge in advanced bioinformatics and Cas protein engineering, allowing the systematic optimization of a more robust system,” says Dr. Giedrius Gasiunas, CSO at Caszyme.

“nSAGE’s long-term vision is to pioneer advancements in both diagnostics and gene therapy, driving the future of precision medicine. In collaboration with Caszyme and Vilnius University, our goal is to develop an ultra-sensitive diagnostic kit that eliminates the need for amplification. This innovation aims to significantly enhance diagnostic accuracy and efficiency, particularly in infectious disease testing, and address a critical gap in Point-of-Care diagnostics,” says Prof. Dr. Bonghee Lee, CEO at nSAGE

“Collaboration bridges expertise and innovation, driving meaningful progress. By partnering with Caszyme and Vilnius University, we are unlocking CRISPR’s full potential. Our goal is to transform its versatility into practical diagnostic solutions,” says Dr. Solji Park, CTO at nSAGE

Source: Caszyme, nSAGE, and Vilnius University Consortium Aims to UNCOVER New Insights With Diagnostics Platform Co-Development